Molecular Network-Selected Pharmacogenomics in a Case of Bipolar Spectrum Disorder

References

• Stahl SM , MorrissetteDA , FaeddaGet al. Guidelines for recognition and management of mixed depression . CNS Spectr.22 ( 2 ), 203 – 219 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Moore TR , HillAM , PanguluriSK . Pharmacogenomics in psychiatry: implications for practice . Recent Pat. Biotechnol.8 ( 2 ), 152 – 159 ( 2014 ).
   PubMedGoogle Scholar
• Buriani A , FortinguerraS , CarraraM . Clinical perspectives in diagnostic-omics and personalised medicine approach to monitor effectiveness and toxicity of phytocomplexes . In : Toxicology of Herbal Product . PelkonenO , DuezP , VuorelaPM , VuorelaH ( Eds ). Springer , NY, USA ( 2016 ).
   Google Scholar
• Domschke K . Clinical and molecular genetics of psychotic depression . Schizophr. Bull.39 ( 4 ), 766 – 775 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Tamatam A , KhanumF , BawaAS . Genetic biomarkers of depression . Indian J. Hum. Genet.18 ( 1 ), 20 – 33 ( 2012 ).
   PubMedGoogle Scholar
• Krishnan V , NestlerEJ . Linking molecules to mood: new insight into the biology of depression . Am. J. Psychiatr.167 ( 11 ), 1305 – 1320 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Kang HJ , KimSY , BaeKYet al. Comorbidity of depression with physical disorders: research and clinical implications . Chonnam Med. J.51 ( 1 ), 8 – 18 ( 2015 ).
   PubMedGoogle Scholar
• Montgomery SA , AsbergM . A new depression scale designed to be sensitive to change . Br. J. Psychiatry134 , 382 – 389 ( 1979 ).
   PubMed Web of Science ®Google Scholar
• Fantino B , MooreN . The self-reported Montgomery–Asberg Depression Rating Scale is a useful evaluative tool in major depressive disorder . BMC Psychiatry9 , 26 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• US FDA . Table of pharmacogenomic biomarkers in drug labeling . www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ucm083378.htm .
   Google Scholar
• Squassina A , ManchiaM , ManolopoulosVGet al. Realities and expectations of pharmacogenomics and personalized medicine: impact of translating genetic knowledge into clinical practice . Pharmacogenomics11 ( 8 ), 1149 – 1167 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Dubovsky SL . The limitations of genetic testing in psychiatry . Psychother. Psychosom.85 , 129 – 135 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Andreou D , SödermanE , AxelssonTet al. Polymorphisms in genes implicated in dopamine, serotonin and noradrenalin metabolism suggest association with cerebrospinal fluid monoamine metabolite concentrations in psychosis . Behav. Brain Funct.29 , 10 – 26 ( 2014 ).
   Google Scholar
• Arango V , HuangY , UnderwoodMD , MannJJ . Genetic of the serotonergic system in suicidal behavior . J. Psychiatr. Res.37 ( 5 ), 375 – 386 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Papakostas GI , FavaM . Biological predictors, moderators and mediators of efficacy . In : Pharmacotherapy for Depression and Treatment-Resistant Depression . World Scientific Publishing Co. Pte. Ltd , Singapore , 371 – 385 ( 2010 ).
   Google Scholar
• Crowley JJ , LipskyRH , LuckiI , BerrettiniWH . Variation in the genes encoding vesicular monoamine transporter 2 and beta-1 adrenergic receptor and antidepressant treatment outcome . Psychiatr. Genet.18 ( 5 ), 248 – 251 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Koo J , LeeMS , HamB , WonES . R347C polymorphism in ADRA1A genes and mirtazapine treatment response in Koreans with major depression . Korean J. Biol. Psychiatry22 ( 4 ), 179 – 186 ( 2015 ).
   Google Scholar
• Glauser TA . Biomarkers for antiepileptic drug response . Biomark. Med.5 ( 5 ), 635 – 641 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Ghodke-Puranik Y , ThornCF , LambaJKet al. Valproic acid pathway: pharmacokinetics and pharmacodynamics . Pharmacogenet. Genomics23 ( 4 ), 236 – 241 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• McCarthy MJ , LeckbandSG , KelsoeJR . Pharmacogenetics of lithium response in bipolar disorder . Pharmacogenomics11 ( 10 ), 1439 – 1465 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Laje G , PaddockS , ManjiHet al. Genetic markers of suicidal ideation emerging during citalopram treatment of major depression . Am. J. Psychiatry164 , 1530 – 1538 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Dwivedi Y , PandeyGN . Adenylyl cyclase-cyclicAMP signaling in mood disorders: role of the crucial phosphorylating enzyme protein kinase A . Neuropsychiatr. Dis. Treat.4 ( 1 ), 161 – 176 ( 2008 ).
   PubMedGoogle Scholar
• Murphy GM , SarginsonJE , RyanHS , O’HaraR , SchatzbergAF , LazzeroniLC . BNDF and CREB1 genetic variants interact to affect antidepressant treatment outcomes in geriatric depression . Pharmacogenet. Genomics23 ( 6 ), 301 – 313 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Lin JY , JiangMY , KanZM , ChuY . Influence of 5-HTR2A genetic polymorphisms on the efficacy of antidepressants in the treatment of major depressive disorder: a meta-analysis . J. Affective Disorders168 , 430 – 438 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Blasi G , SelvaggiP , FazioLet al. Variation in dopamine D2 and serotonin 5-HT2A receptor genes is associated with working memory processing and response to treatment with antipsychotics . Neuropsychopharmacology40 ( 7 ), 1600 – 1608 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Reynolds GP , McGowanOO , DaltonCF . Pharmacogenomics in psychiatry: the relevance of receptor and transporter polymorphisms . Br. J. Clin. Pharmacol.77 ( 4 ), 654 – 672 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Cooper JM , NewbyDA , WhyteIM , CarterG , JonesAL , IsbisterGK . Serotonin toxicity from antidepressant overdose and its association with the T102C polymorphism of the 5-HT2A receptor . Pharmacogenomics J.14 , 390 – 394 ( 2014 ).
   PubMed Web of Science ®Google Scholar